FINHUB Insights

DVA · Q3 FY25 · Jul 1 – Sep 30, 2025

DaVita Q3 FY25: where the revenue came from and where it went

DaVita Q3 FY25: revenue $3.4B (+5% year over year). Net profit $0.2B. Largest cohort U.S.Dialysis and Related Lab $3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 29, 2025 10-Q
Sankey diagram of DaVita's income statement for Q3 FY25: revenue of $3.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.4B +5% year over year
Operating profit$0.5B 15% margin
Net profit$0.2B 4% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.4 100% +5%
U.S.Dialysis and Related Lab 3 88% +3%
All Other Segments 0.5 15% +21%
Patient care−2.368%+0pp
General and administrative−0.412%+0pp
Depreciation and amortization−0.25%+0pp
Operating profit0.515% margin−2pp
Tax−0.1
Interest & other costs−0.2
Net profit0.24%−2pp
Filing on EDGAR More quarters of DVA

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters